Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of Gemcabene in Patients with Homozygous Familial Hypercholesterolemia

Trial Profile

A Phase III Study of Gemcabene in Patients with Homozygous Familial Hypercholesterolemia

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Dyslipidaemias; Hyperlipoproteinaemia type IIa
  • Focus Registrational; Therapeutic Use
  • Sponsors Gemphire Therapeutics; NeuroBo Pharmaceuticals
  • Most Recent Events

    • 11 Aug 2020 According to a NeuroBo Pharmaceuticals media release, the company announced that in May 2020, it received written communication from the FDA stating that the clinical development program for Gemcabene remains on a partial clinical hold. The Company is reviewing its options regarding Gemcabene.
    • 15 Mar 2019 According to a Gemphire Therapeutics media release, the FDA denied the request to lift partial clinical hold in Q3 2018 and requested additional information in order to resubmit. End of Phase 2 meeting would not take place until the partial clinical hold is lifted. Company expect to submit the additional information to the FDA in the Q4 of 2019. Management need to raise capital to complete additional activities needed to susubmit our request to the FDA to lift the partial clinical hold.
    • 13 Aug 2018 According to a Gemphire Therapeutics media release, the company is working with the FDA to release the partial hold on gemcabene with respect to clinical trials of longer than six months in duration, with the goal of proceeding to an End of Phase 2 meeting and reaching an agreement on the design of this Phase 3 clinical trial in dyslipidemia. It plans to conduct the studies required by the FDA and expects to submit the additional results in the second quarter of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top